106-120 of 931
Screening Modalities for Colon Cancer: What You Need to Know
GI InsightsScreening Modalities for Colon Cancer: What You Need to Know
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Charles Turck, PharmD, BCPS, BCCCP
Matthew Hadfield, MD
Redefining Cancer Care with Functional Precision Medicine
Project Oncology®Redefining Cancer Care with Functional Precision Medicine
Matt Birnholz, MD
Jim Foote, MBA
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Project Oncology®Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
- advertisement
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
Communicating Pathologic Response Results in Resectable NSCLC
Project Oncology®Communicating Pathologic Response Results in Resectable NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Alexander Spira, MD, PhD, FACP
Robert Merritt, MD
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Project Oncology®Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Deepa Rangachari, MD
Managing Immune-Related Adverse Events in Metastatic NSCLC
Project Oncology®Managing Immune-Related Adverse Events in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Paul Bunn, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
- advertisement
How KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Clinician's RoundtableHow KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Brian P. McDonough, MD, FAAFP
Thanai Pongdee, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP